Federated Investors Inc. PA lifted its position in shares of ChemoCentryx Inc (NASDAQ:CCXI) by 23.7% in the second quarter, HoldingsChannel reports. The institutional investor owned 66,569 shares of the biopharmaceutical company’s stock after acquiring an additional 12,759 shares during the period. Federated Investors Inc. PA’s holdings in ChemoCentryx were worth $877,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of CCXI. Carmignac Gestion acquired a new position in ChemoCentryx in the first quarter valued at about $5,305,000. Millennium Management LLC raised its stake in ChemoCentryx by 26.7% in the first quarter. Millennium Management LLC now owns 324,112 shares of the biopharmaceutical company’s stock valued at $4,408,000 after purchasing an additional 68,281 shares in the last quarter. Spark Investment Management LLC raised its stake in ChemoCentryx by 161.8% in the second quarter. Spark Investment Management LLC now owns 163,900 shares of the biopharmaceutical company’s stock valued at $2,158,000 after purchasing an additional 101,300 shares in the last quarter. P.A.W. Capital Corp raised its stake in ChemoCentryx by 13.3% in the second quarter. P.A.W. Capital Corp now owns 85,000 shares of the biopharmaceutical company’s stock valued at $1,119,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in ChemoCentryx in the first quarter valued at about $196,000. 54.43% of the stock is owned by institutional investors.

In other ChemoCentryx news, insider Markus J. Cappel sold 25,179 shares of ChemoCentryx stock in a transaction dated Friday, June 29th. The stock was sold at an average price of $13.67, for a total value of $344,196.93. Following the transaction, the insider now owns 24,626 shares in the company, valued at $336,637.42. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Susan M. Kanaya sold 49,507 shares of ChemoCentryx stock in a transaction dated Thursday, June 28th. The shares were sold at an average price of $13.79, for a total value of $682,701.53. Following the completion of the transaction, the chief financial officer now owns 38,985 shares in the company, valued at approximately $537,603.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 76,436 shares of company stock worth $1,050,371. Company insiders own 14.50% of the company’s stock.

ChemoCentryx stock opened at $12.91 on Monday. ChemoCentryx Inc has a 12-month low of $5.42 and a 12-month high of $15.08. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $634.53 million, a price-to-earnings ratio of 37.97 and a beta of 1.36.

ChemoCentryx (NASDAQ:CCXI) last released its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01. ChemoCentryx had a return on equity of 39.31% and a net margin of 18.69%. The firm had revenue of $15.02 million for the quarter, compared to analysts’ expectations of $16.88 million. equities analysts anticipate that ChemoCentryx Inc will post -0.86 earnings per share for the current fiscal year.

A number of research analysts recently commented on CCXI shares. BidaskClub downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Saturday, September 8th. ValuEngine downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Friday, September 7th. Canaccord Genuity reaffirmed a “buy” rating and issued a $18.00 price target on shares of ChemoCentryx in a research note on Friday, August 10th. JPMorgan Chase & Co. cut ChemoCentryx from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $14.00 to $15.00 in a research report on Tuesday, August 14th. Finally, Zacks Investment Research cut ChemoCentryx from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 3rd. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. ChemoCentryx has a consensus rating of “Buy” and a consensus price target of $16.58.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).

Read More: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx Inc (NASDAQ:CCXI).

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.